Received: 15 December 2020
Accepted: 13 March 2021
First Online: 26 March 2021
: This study was reviewed, and ethics clearance granted by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (DMED-1914–16). All participants reviewed and provided signed consent prior to study enrollment.
: Participants provided such consent as part of the informed consent form.
: AKE has participated in advisory boards for ALK-Abelló, AstraZeneca, Aralez, Bausch Health, Circassia Ltd, GlaxoSmithKline, LEO Pharma, Johnson & Johnson, Merck, Mylan, Novartis, Pediapharm and Pfizer, has been a speaker for ALK, Aralez, AstraZeneca, Boerhinger-Ingelheim, CACME, Meda, Mylan, Merck, Novartis, Pediapharm, Pfizer, The ACADEMY, and Takeda. Her institution has received research grants from Bayer LLC, Circassia Ltd, Green Cross Pharmaceuticals, GlaxoSmithKline, Sun Pharma, Merck, Novartis, Pfizer, Regeneron and Sanofi. She has also served as an independent consultant to Allergy Therapeutics, Bayer LLC, Ora Inc. and Regeneron in the past.